Oral GLP-1 Medications in the UK: The Complete Guide

Oral GLP-1 medications are once-daily tablets that work in a similar way to weight-loss injections such as Wegovy and Mounjaro, by acting on GLP-1 receptors to reduce appetite and slow stomach emptying. In the UK, two are now licensed for weight management: Wegovy tablets (oral semaglutide), authorised by the MHRA in June 2026, and Foundayo (orforglipron), authorised in August 2026. A third, Rybelsus, is an oral semaglutide tablet licensed only for type 2 diabetes. All are prescription-only. This guide explains how they differ, what the trials show, how they are taken and what to consider.

Why GLP-1 tablets are a big development

Until 2026, the GLP-1 medicines licensed for weight management in the UK were all injections: Saxenda (daily), Wegovy (weekly) and Mounjaro (weekly, a dual GIP/GLP-1 agonist). Injections work well for many people, but some find them off-putting because of needle anxiety, the need for refrigeration, or simply a preference for tablets.

Tablets could also matter at a population level. They are easier to store and distribute, do not require needles or sharps disposal, and may in time be cheaper to manufacture, particularly small-molecule drugs like orforglipron. Whether that translates into wider access will depend on pricing, NICE decisions and supply.

The oral GLP-1 medicines at a glance

Licence details summarised from the SmPCs on medicines.org.uk and MHRA announcements. Check the current SmPC for exact wording.

How oral GLP-1s work

All three medicines activate the GLP-1 receptor, mimicking a natural gut hormone. The effects are the same as with injectable GLP-1s:

• reduced appetite and earlier fullness, through action on the brain
• slower stomach emptying
• improved insulin release and lower glucagon when blood glucose is high

The difference lies in how the medicine gets into the body.

Semaglutide tablets: a peptide that needs help

Semaglutide is a peptide, a chain of amino acids similar to the natural hormone. Peptides are normally broken down by stomach acid and digestive enzymes, and they are poorly absorbed through the gut wall. That is why most peptide medicines, including insulin, are injected.

Oral semaglutide gets around this by combining the drug with an absorption enhancer called SNAC (salcaprozate sodium). SNAC creates a small zone of raised pH around the tablet in the stomach, protecting semaglutide from breakdown and helping it pass through the stomach lining. Even so, only a small fraction of each dose is absorbed. That is why:

• oral doses are much larger in milligrams than injected doses (25mg daily vs 2.4mg weekly)
• food, larger volumes of drink and other tablets in the stomach can sharply reduce absorption
• the tablet must be taken on an empty stomach with a small sip of water, followed by a wait

Orforglipron: a small molecule

Orforglipron is not a peptide. It is a small-molecule drug designed to bind to and activate the GLP-1 receptor. Small molecules are generally absorbed more predictably from the gut, which is why Foundayo can be taken with or without food and at any time of day. Small-molecule drugs are also processed by the liver in ways peptides are not, which creates some different interactions, for example with certain medicines that affect the liver enzyme CYP3A4.

Our guides to oral semaglutide and Foundayo explain each medicine in more depth.

What the trials show

Wegovy tablets: OASIS trials

The OASIS programme tested oral semaglutide for weight management.

• OASIS 4 (NEJM, 2025) tested the 25mg dose that is now licensed. Adults with obesity, or overweight with a weight-related condition, without diabetes, lost an average of 13.6% of their body weight over 64 weeks, compared with 2.2% on placebo. Around three-quarters lost at least 5%, and more than a quarter lost at least 20%.
• OASIS 1 (The Lancet, 2023) tested a higher 50mg dose and found an average weight loss of about 15% at 68 weeks, compared with about 2.4% on placebo. The 50mg dose is not the licensed UK dose.

Foundayo: ATTAIN trials

• ATTAIN-1 (NEJM, 2025) enrolled 3,127 adults with obesity, or overweight with a weight-related condition, without diabetes. Over 72 weeks, average weight loss was 7.8%, 9.3% and 12.4% on the three trial doses, compared with 0.9% on placebo (efficacy estimand; the treatment-regimen estimand, which counts people who stopped treatment, gave somewhat lower figures).
• ATTAIN-MAINTAIN tested switching to orforglipron after weight loss on injectable semaglutide or tirzepatide. Topline results reported by Eli Lilly suggested orforglipron helped maintain much of the weight lost, more so after switching from semaglutide than from tirzepatide. Full peer-reviewed publication should be checked for details.

Note that the trials used capsules, and the UK-marketed Foundayo tablets use different milligram strengths. The SmPC states that trial doses of 6mg, 12mg and 36mg correspond to tablet doses of 5.5mg, 9mg and 17.2mg.

How they compare with injections

These trials enrolled different people at different times, with different methods, so the figures cannot be compared directly. Head-to-head trials are the most reliable way to compare medicines, and few exist for these pairings. Broadly, oral semaglutide 25mg appears to perform similarly to injectable semaglutide 2.4mg, orforglipron somewhat less on average at its highest dose, and tirzepatide injections more. Our guide to tablets vs injections looks at this in more detail.

How the tablets are taken

Wegovy tablets

According to the UK SmPC:

• Start at 1.5mg once daily for at least a month, then increase to 4mg, 9mg and 25mg, spending at least a month at each step.
• Take the tablet on an empty stomach, after fasting for at least eight hours (for most people, first thing in the morning).
• Swallow it whole with a sip of water, up to half a glass (120ml).
• Wait at least 30 minutes before eating, drinking or taking other oral medicines.
• If you miss a dose, skip it and take the next dose the following day.

These rules matter. Taking the tablet with food, with a large glass of water or alongside other tablets can significantly reduce how much semaglutide is absorbed.

Foundayo

According to the UK SmPC:

• Start at 0.8mg once daily, then increase to 2.5mg after at least 30 days, then 5.5mg. Further increases to 9mg, 14.5mg or 17.2mg may follow, each after at least 30 days, depending on response and tolerability.
• The maximum dose is 17.2mg once daily. You should not take more than one tablet a day to make up a higher dose.
• Take it at any time of day, with or without food or water restrictions.
• If you miss a dose, take it as soon as possible, but never take more than one tablet in a day.

Side effects

Because they act on the same receptor, oral GLP-1s cause side effects very similar to injectable versions. The most common are gastrointestinal:

• nausea
• vomiting
• diarrhoea
• constipation
• indigestion, abdominal pain and bloating

In OASIS 4, nausea was reported by about 47% of people on oral semaglutide (vs about 19% on placebo) and vomiting by about 31% (vs about 6%). In ATTAIN-1, gastrointestinal effects were the most common, mostly mild to moderate, and stopping because of side effects ranged from about 5% to 10% across the orforglipron doses, compared with about 3% on placebo.

Both SmPCs list serious but less common risks shared across the GLP-1 class, including pancreatitis, gallbladder problems, dehydration and kidney injury, and aspiration risk under anaesthesia. Our guide to oral GLP-1 side effects explains how they are managed.

Interactions and practical considerations

Wegovy tablets

• Other morning medicines must wait at least 30 minutes after the tablet.
• Levothyroxine: studies showed increased thyroxine exposure, so thyroid levels may need monitoring.
• Warfarin: INR monitoring is advised when starting.

Foundayo

• Oral contraceptives: the SmPC states orforglipron may reduce the effectiveness of oral hormonal contraceptives. It advises switching to a non-oral method, or adding a barrier method, for 30 days after starting and for 30 days after each dose increase.
• CYP3A4 and OATP1B interactions: some medicines that strongly inhibit or induce these pathways can change orforglipron levels, and simvastatin doses may need adjusting.

Always give your prescriber a full list of your medicines and supplements. Our guide to GLP-1 medication interactions covers this in depth.

Pregnancy

Neither tablet should be used in pregnancy. The Wegovy tablets SmPC advises stopping at least two months before a planned pregnancy; the Foundayo SmPC advises stopping at least three weeks before. Both advise against use while breastfeeding. See our pregnancy and fertility guide.

Who might a tablet suit?

There is no single "right" choice between a tablet and an injection. Factors a prescriber might discuss with you include:

• Needle anxiety. Tablets avoid injections entirely.
• Routine. Weekly injections suit some people better than a daily tablet; for others, a daily tablet fits more easily into a routine.
• Morning schedule. Oral semaglutide's fasting and waiting rules suit people who can reliably take it on waking and wait before breakfast. Foundayo's flexibility may suit people with irregular routines.
• Other medicines. Interactions, particularly with contraceptives (Foundayo) or levothyroxine (oral semaglutide), may influence the choice.
• Expected weight loss. On average, tirzepatide injections produced the most weight loss in trials.
• Cardiovascular evidence. At the time of writing, the SELECT cardiovascular outcome evidence applies to semaglutide injections, not to the tablets.
• Travel and storage. Tablets do not need refrigeration.
• Cost and access. Costs vary by medicine, dose and provider. Our prices page explains the factors involved.

NHS and private access

At the time of writing:

• Wegovy tablets had not been recommended by NICE for weight management, so they were not routinely available on the NHS.
• Foundayo was being assessed by NICE, with draft guidance expected in November 2026.
• Rybelsus is available on the NHS for type 2 diabetes.

Both weight-management tablets are available on private prescription from regulated providers, which should carry out a full assessment, including verifying your identity and weight. Our provider comparison explains how services differ, and our guide to how to choose an online pharmacy covers what to check.

Switching between injections and tablets

The Wegovy tablets SmPC states that people on semaglutide 2.4mg injections can switch directly to 25mg tablets, starting one week after the last injection. Switching from tirzepatide, or to Foundayo, is less clearly defined in product information, and the ATTAIN-MAINTAIN trial is the main source of evidence on switching to orforglipron. Our guide to switching from an injection to a tablet explains what to consider. Any switch should be planned with a prescriber.

Living with a daily GLP-1 tablet

Moving from a weekly injection to a daily tablet, or starting on a tablet from scratch, changes the rhythm of treatment. A few practical points come up often.

Building the routine

A daily tablet is easy to forget in a way a weekly injection is not, and it is also easier to miss a single dose without much consequence. Linking the tablet to something you already do every day (waking up, brushing your teeth, putting the kettle on) helps. Phone reminders and pill organisers work for many people. For oral semaglutide, keeping the tablets beside your bed with a small glass ready makes the empty-stomach routine simpler.

Travel and time zones

Tablets do not need refrigeration, which makes travel easier than with pens. Keep them in their original packaging, in your hand luggage, with a copy of your prescription. When crossing time zones, aim to keep roughly 24 hours between doses. For oral semaglutide, remember that the fasting and 30-minute rules still apply in a new time zone; for Foundayo, timing is more flexible.

Illness and vomiting

If you are unwell with vomiting or diarrhoea, you may lose fluids quickly, and GLP-1 medicines can make dehydration more likely. Try to keep sipping fluids. If you cannot keep fluids down, have signs of dehydration, or are unwell for more than a day or two, contact your prescriber or NHS 111 for advice about whether to pause treatment. If you have diabetes, follow any sick-day rules your diabetes team has given you.

Alcohol

There is no specific ban on alcohol with GLP-1 tablets, but alcohol can worsen nausea and reflux, adds calories, and in people taking diabetes medicines can contribute to low blood sugar. Many people find they want less alcohol on GLP-1 treatment. Our guide to Mounjaro and alcohol covers the general principles, which apply across GLP-1 medicines.

Myths about GLP-1 tablets

"Tablets are a weaker version of the injections." Oral semaglutide 25mg produced average weight loss close to that of semaglutide injections in separate trials. Orforglipron's average results were somewhat lower than injectable semaglutide or tirzepatide, but still substantial. "Weaker" is too simple a description.

"Tablets have no side effects because you are not injecting." Side effects come from how the medicine acts on the body, not the route. Gastrointestinal effects are just as common with tablets.

"You can get GLP-1 tablets without a prescription." All licensed GLP-1 tablets are prescription-only. Products sold without a prescription are not licensed medicines and may be unsafe.

"Any GLP-1 tablet will do." Wegovy tablets, Rybelsus and Foundayo differ in licence, dose, how they are taken and interactions. They are not interchangeable.

Questions to ask a prescriber

• Is a tablet or an injection more suitable for my health, routine and goals?
• Which tablet would you suggest, and why?
• How should I take it, and what should I do if I miss a dose?
• Do any of my current medicines, including contraception, interact with it?
• What weight loss would be a reasonable expectation, and when will we review progress?
• What happens if I want to stop or switch later?

What else is coming?

Several other oral weight-management medicines are in development, including higher-dose and next-generation oral GLP-1 and combination drugs. Our guide to the GLP-1 pipeline covers what is in trials and the likely timelines. Be cautious of anything sold as a "GLP-1 pill" that is not a licensed medicine: supplements marketed as "natural GLP-1" or "GLP-1 boosters" are not equivalent and have not been shown to produce similar effects. Our guide to weight loss tablets in the UK explains what is licensed.

When to speak to a professional

Speak to your GP, pharmacist or prescriber if:

• You are considering a GLP-1 tablet and want to know whether it is suitable for you.
• You take levothyroxine, warfarin, the contraceptive pill or other regular medicines.
• You are planning a pregnancy, are pregnant or are breastfeeding.
• Side effects are affecting your ability to eat or drink normally.
• You are unsure how to take your tablet correctly.
• You want to switch between an injection and a tablet.

Seek urgent medical help (NHS 111, or 999 in an emergency) if you have:

• Severe, persistent abdominal pain, which may spread to your back, with or without vomiting (possible pancreatitis).
• Pain in the upper right abdomen, fever, or yellowing of the skin or eyes (possible gallbladder problems).
• Persistent vomiting or diarrhoea with signs of dehydration, such as dizziness or passing very little urine.
• Signs of a severe allergic reaction, such as swelling of the face or throat or difficulty breathing.
• Sudden loss of vision or blurred vision in one eye.

For more on oral treatments, visit our oral GLP-1 hub. Whether a tablet, an injection or another approach is right for you is a decision for a qualified prescriber.